Search Results - "Leahy, Terri"

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer by Nishio, Shin, Takekuma, Munetaka, Takeuchi, Satoshi, Kawano, Kouichirou, Tsuda, Naotake, Tasaki, Kazuto, Takahashi, Nobutaka, Abe, Masakazu, Tanaka, Aki, Nagasawa, Takayuki, Shoji, Tadahiro, Xiong, Hao, Nuthalapati, Silpa, Leahy, Terri, Hashiba, Hideyuki, Kiriyama, Tsukasa, Komarnitsky, Philip, Hirashima, Yasuyuki, Ushijima, Kimio

“…This phase 1, open‐label, dose‐escalation study was conducted to determine the safety, tolerability, pharmacokinetics and preliminary efficacy of veliparib…”
Get full text

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors by Nishikawa, Tadaaki, Matsumoto, Koji, Tamura, Kenji, Yoshida, Hiroyuki, Imai, Yuichi, Miyasaka, Aki, Onoe, Takuma, Yamaguchi, Satoshi, Shimizu, Chikako, Yonemori, Kan, Shimoi, Tatsunori, Yunokawa, Mayu, Xiong, Hao, Nuthalapati, Silpa, Hashiba, Hideyuki, Kiriyama, Tsukasa, Leahy, Terri, Komarnitsky, Philip, Fujiwara, Keiichi

“…Veliparib (ABT‐888) is a potent, orally bioavailable poly(ADP‐ribose) polymerase‐1 and ‐2 inhibitor. This phase 1 study evaluated the tolerability,…”
Get full text

Phase 0 Trials: An Industry Perspective by Eliopoulos, Helen, Giranda, Vincent, Carr, Robert, Tiehen, Rita, Leahy, Terri, Gordon, Gary

“…Worldwide, cancer is a leading cause of morbidity and mortality. An increased understanding of the disease and its process has resulted in a multitude of new…”
Get full text

Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics by CARDUCCI, Michael A, NELSON, Joel B, JANUS, Todd J, ANDRE, Amy, HOSMANE, Balakrishna S, PADLEY, Robert J, BOWLING, M. Kathy, ROGERS, Theresa, EISENBERGER, Mario A, SINIBALDI, Victoria, DONEHOWER, Ross, LEAHY, Terri L, CARR, Robert A, ISAACSON, Jeffrey D

“…Endothelin receptors, particularly the ET(A) receptor, have been shown to participate in the pathophysiology of prostate and other cancers. Atrasentan, an…”
Get full text

Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: An endothelin receptor antagonist for refractory prostate cancer by ZONNENBERG, Bernard A, GROENEWEGEN, Gerard, JANUS, Todd J, LEAHY, Terri W, HUMERICKHOUSE, Rod A, ISAACSON, Jeffrey D, CARR, Robert A, VOEST, Emile

“…Evidence suggests that endothelin (ET)-1 and its primary receptor, the ET(A) receptor, may contribute to the progression of prostate and other cancers…”
Get full text

Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study by Mehta, Minesh P., Wang, Ding, Wang, Fen, Kleinberg, Lawrence, Brade, Anthony, Robins, H. Ian, Turaka, Aruna, Leahy, Terri, Medina, Diane, Xiong, Hao, Mostafa, Nael M., Dunbar, Martin, Zhu, Ming, Qian, Jane, Holen, Kyle, Giranda, Vincent, Curran, Walter J.

“…Veliparib, a potent, oral PARP inhibitor, potentiates the antitumor activity of radiation therapy and crosses the blood–brain barrier. This was a phase 1…”
Get full text

A phase 3 randomized trial of veliparib (ABT-888) plus carboplatin and paclitaxel versus investigator’s choice of standard chemotherapy in previously untreated patients with metastatic/advanced non-squamous (NSq) non-small cell lung cancer (NSCLC) by McKee, Mark D., Pedersen, Michelle, DeLuca, Angela, Qin, Qin, Qian, Jane, Irving, Jade, Ansell, Peter, Leahy, Terri, Caskey, Courtney, Giranda, Vincent L.

“…Abstract only…”
Get full text

Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases by Mehta, Minesh P., Curran, Walter J., Wang, Ding, Wang, Fen, Kleinberg, Lawrence, Brade, Anthony M., Mostafa, Nael, Zhou, Xiangdong, Qian, Jiang, Leahy, Terri, Desai, Bhardwaj, Giranda, Vincent L.

“…Abstract only 2013 Background: Veliparib is an oral PARP-1 and -2 inhibitor that enhances the antitumor activity of DNA damaging agents including radiation…”
Get full text

Phase 0 Trials : An Industry Perspective : FOCUSON Phase O Clinical trials by ELIOPOULOS, Helen, GIRANDA, Vincent, CARR, Robert, TIEHEN, Rita, LEAHY, Terri, GORDON, Gary

Get full text

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan by Bernard A. Zonnenberg, Gerard Groenewegen, Todd J. Janus, Terri W. Leahy, Rod A. Humerickhouse, Jeffrey D. Isaacson, Robert A. Carr, Emile Voest

“…Purpose: Evidence suggests that endothelin (ET)-1 and its primary receptor, the ET A receptor, may contribute to the progression of prostate and other cancers…”
Get full text